Anti-Mouse I-A/I-E (MHC Class II) - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

C57BL/6 Spleen Cells

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

RRID

AB_2892894

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for this Clone M5/114.15.2 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

IHC FF
B
IP

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone M5/114.15.2 recognizes an epitope on the mouse MHC class II molecules I-A^b, I-A^d, I-A^q, I-E^d, and I-E^k. Clone M5/114.15.2 does not react with I-A^f, I-A^k, or I-A^s.

Antigen Distribution

I-A^b/d/q and I-E^d/k are expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells from mice of the I-A^b/d/q and I-E^d/k haplotypes.

Background

MHC class II antibody, clone M5/114.15.2, recognizes the major histocompatibility complex (MHC) class II molecules I-A^b, I-A^d, I-A^q, I-E^d, and I-E^k. MHC class II is constitutively expressed on professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation¹. MHC class II consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain². The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens³. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling⁴. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation⁵ and can transduce signals into T cells, enhancing T cell proliferation and activity⁶.

Antigen Details

Protein

I-A/I-E

Ligand/Receptor

CD3/TCR, CD4

PubMed

I-A/I-E

NCBI Gene Bank ID

14961

UniProt.org

Information on Uniprot.org

Research Area

Immunology

.

Innate Immunity

References & Citations

1. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90
2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25
3. Wieczorek M, et al. (2017) Front Immunol. 8:292
4. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
5. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5
6. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60

Technical Protocols